The introduction of Retatrutide ZPHC, at a dosage of 120mg, is generating considerable interest within the weight loss community. This groundbreaking dual GIP and GLP-1 agonist medication seems to deliver impressive improvements in weight reduction compared to current therapies. Initial clinical trials have demonstrated marked reductions in weight